Page 528 - Traité de chimie thérapeutique 6 Médicaments antitumoraux

486 MEDICAMENTSINDUISANTOUSTABILISANTDES COUPURESDE L'ADN

POLVERINI P.J., NOVAK R.F., Inhibition of angiogenesis by the antineoplastic agents
mitoxantrone and bisantrene, Biochem. Biophys. Res. Commun., 1986, 140, 901-907.
RYBAK M.E. et al., The effects of bisantrene on human platelets, lnvest. New Drugs,
1986, 4, 119-125.

MÉCANISME D'ACTION
DOROSHOW J.H. et al., Comparative cardiac oxygen radical metabolism by anthracy-
cline antibiotics, mitoxantrone, bisantrene, 4'-(9-acridinylamino)-methanesulfon-m-
anisidide, and neocarzinostatin, Biochem. Pharmacol., 1983, 39, 2935-2939.
BOWDEN G.T. et al., Comparative molecular pharmacology in leukemic L 1210 cells of
the anthracene anticancer drugs mitoxantrone and bisantrene, CancerRes., 1985, 45,
4915-4920.
CHEN K.X. et al., lntercalative binding and antitumor activity of bisantrene and derivati-
ves, /nt. J. Quantum Chem., Quantum Biot. Symp., 1987, 14, 15-25.
ELLIOTT J.A. et al., Interaction of bisantrene anticancer agents with DNA : footprinting,
structural requirements for DNA unwinding, kinetics and mechanism of binding and
correlation of structural and kinetic parameters with anticancer activity, Anti-cancer
Drug Des., 1989, 3, 271-282.
MURDOCK K.C. et al., DNA Binding by antitumoranthracene derivatives, J. Med. Chem.,
1990, 33, 1549-1553.
PERRIN D. et al., Differential sensitivities of recombinant human topoisomerase Il a and
B interacting agents, Biochem Pharmaco/., 1998, 56, 503-507.
WUNZ T.P. et al., DNA binding by antitumor anthracene derivatives, J. Med. Chem.,
1990, 33, 1549-1553.
IYENGAR B.S. et al., 1,4-Disubstituted anthracene antitumor agents, J. Med. Chem.,
1997, 40, 3734-3738.
CAPRANICO G. et al., A protein-mediated mechanism for the DNA sequence-specific
action of topoisomerase Il poisons, Trends Pharmacol. Sci., 1997, 18, 323-329.
CAPRANICO G. et al., Mapping drug interactions at the covalent topoisomerase II-DNA
complex by bisantrene/amsacrine congeners, J. Biol. Chem., 1998, 273, 12732-
12739.
SISSI C. et al., DNA-binding preferences of bisantrene analogs : relevance to the
sequence specificity of drug-mediated topoisomerase Il poisoning, Mol. Pharmacol.,
1998, 54, 1036-1045.
VENITT S. et al., Anthracene-9,10-diones as potential anticancer agents : bacterial
mutation studies of amido-substituted derivatives reveal an unexpected lack of muta-
genicity, J. Med. Chem., 1998, 41, 3748-3752.
ZAGOTTO, G. et al., Synthesis, DNA-damaging and cytotoxic properties of novel topoi-
somerase 11-directed bisantrene analogs, Bioorg. Med. Chem. Lett., 1998, 8, 121-126.

RÉSISTANCE
ZHANG X. et al., P-glycoprotein mediates profound resistance to bisantrene, Oncol.
Res., 1994, 6, 291-301.
ZHOU Y. et al., Domain exchangeability between the multidrug transporter (MDR1) and
phosphatidylcholine flippase (MDR2), Mol. Pharmacol., 1999, 56, 997-1004.